drugset / Trial / NCT02701166

Summary

Randomized double blind placebo controlled trial to evaluate the antipruritic effect of bezafibrate in patients with moderate to severe cholestatic itch.

Timeline

Start
2016-02
Primary completion
2018-02
Completion
2018-04

Outcome

Met primary endpoint

paper For the primary end point, bezafibrate led in 45% (41% PSC, 55% PBC) and placebo in 11% to ≥50% reduction of severe or moderate pruritus (P = .003). PMID 33031833 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bezafibrate Small molecule 400 mg —